USA Technegas Expansion Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Cyclopharm Limited has provided an update on its expansion efforts for Technegas in the United States, highlighting recent agreements and installations at major health systems. The company is leveraging existing relationships to enhance its network and has secured new contracts, including installations at prominent hospitals. Cyclopharm anticipates that the inclusion of Technegas in clinical guidelines will further boost its adoption in the market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Cyclopharm
- CYC Secures Multi-Site Agreement with Northwestern Medicine
- CYC Signs Enterprise Agreement with UPHS
- Preliminary Final Report
- Technegas US Footprint Expanding Across Four Regions
- Technegas Approved at the US National Institutes of Health
Later from Cyclopharm
- CYC First-Half 2026 Update
- Immediate 11-Site Technegas Rollout at University Hospitals
- New US Lung Imaging Guidelines Name Technegas as Preferred A
- CYC 1H2026 Results Summary
- Chinese Consensus Names Technegas Preferred Lung Agent
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm